Citi raised the firm’s price target on Bruker (BRKR) to $53 from $40 and keeps a Neutral rating on the shares. The firm adjusted targets in the life science tools and diagnostics group after meeting with companies. Commentary around pharma was positive, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker: Solid Q4 Momentum and Reaffirmed 2026 Targets Underpin Buy Rating and Upside Potential
- Bruker clarifies regulatory filing status in recent 8-K
- Bruker sees Q4 preliminary revenue $965M-$970M, consensus $958.3M
- Bruker sees 2026 organic revenue growth of flat to up low-single digits
- Bruker announces $500M multi-year supply agreements for superconductors